Pharmaceutical company intelligence

Seraph Pharmaceutical

Pharmaceutical manufacturer · Islamabad · Pakistan

Islamabad-based pharmaceutical manufacturer producing general and cephalosporin dosage forms including tablets, capsules, topicals and injectables.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.

Official website ↗

Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details

Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase

Latest portfolio source check27 Aug 2026Latest source-check date across this published portfolio

Latest effective price date1 Jul 2024Newest effective date among published current price records

Corporate profile evidence3 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Location intelligence

Company location

Google Maps

Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗

Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view

Rx109public portfolio records represented

REG74unique registrations represented

IDX103indexed MedInfoBase presentations

SRC5additional source-observed presentations

R+1registry-only registrations

VER0registry-verified exact registrations

PKR103current validated price records

G35generic molecules in indexed catalogue

DF10dosage-form groups

TA7therapeutic areas

How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%

public portfolio presentations with a validated current price

Official-source coverage100%

products linked back to a source record

Unit-price parse coverage100%

priced packs safely normalized per unit

Comparable-market coverage94%

products with at least one like-for-like comparator

Therapeutic classification100%

products assigned to a broad therapeutic area

Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives57 products · 55%

CNS & mental health29 products · 28%

Dermatology5 products · 5%

Gastrointestinal & hepatology5 products · 5%

Oncology & immunology4 products · 4%

Cardiovascular2 products · 2%

Other specialty1 products · 1%

Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins19 products · 18%

Antipsychotics12 products · 12%

Antiepileptics12 products · 12%

Macrolide antibacterials8 products · 8%

Fluoroquinolone antibacterials6 products · 6%

Antifungals5 products · 5%

Antipsoriatic medicines5 products · 5%

Antiparasitic medicines5 products · 5%

Formulation footprint

Dosage forms

Tablet48 products

Injection30 products

Cream7 products

Capsule6 products

Lotion3 products

Solution3 products

Gel2 products

Suspension2 products

Infusion1 products

Ointment1 products

How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales

#1 DroncefCeftriaxone 12presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 LevaceLevetiracetam 10presentations 100 mg, 100 mg/mL, 250 mg, 500 mg · Injection, Solution, Tablet #3 OrisRisperidone 6presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #4 CequelQuetiapine 5presentations 100 mg, 25 mg, 300 mg · Tablet #5 CartrialCalcipotriol 4presentations 0.005%, 0.05 mg, 0.05 mg/g · Cream #6 Zyban 150mg SRBupropion 4presentations 150 mg · Tablet

Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis

Below market median5658% of comparable products

Near market median36within ±5% of median

Above market median55% of comparable products

Lowest-price equivalents9ties included

Company median price position -6.9% relative to the median unit price of like-for-like equivalent products.

Most competitively positioned examplesProducts with at least 3 market comparators

Zyban 300 mgBupropion · Sustained-release tablet · 2x10's PKR 47.07/tablet-47.3% vs market median Sthrin 5%Permethrin · Cream · 30gm PKR 2.48/g-36.5% vs market median Actarin 20 mg/gMiconazole · Gel · 20 gm PKR 6.78/g-22.3% vs market median Sephrix B 0.5 mgEntecavir · Tablet · 3x10's PKR 280.20/tablet-21.3% vs market median Icunem 1 gMeropenem · Injection · 1's PKR 3,188.94/vial/unit-19.5% vs market median

How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 26shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 26shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 24shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 23shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 23shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 22shared generics

Regulatory & price activity

Observed database signals

Indexed registration numbers71Distinct registrations among indexed, published, presentation-validated products only

Verified price observations103

Products with a verified price103

Products with multiple price observations0

Source records with multiple versions102

Latest portfolio source check27 Aug 2026

Latest effective price date1 Jul 2024

Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

74 unique registration(s) · 103 indexed presentation(s) · 5 additional source-observed presentation(s) · 1 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Brand	Generic	Strength	Form	Pack	Registration	Source-listed price	Unit price	Price position
Tefotaxime	Cefotaxime	250 mg	Injection	1's	086240	PKR 89.01	PKR 89.01/vial/unit	16% below median
Tefotaxime	Cefotaxime	500 mg	Injection	1's	086241	PKR 163.19	PKR 163.19/vial/unit	Near median
Tefotaxime	Cefotaxime	1 g	Injection	1's	086242	PKR 237.37	PKR 237.37/vial/unit	17% below median
Trispan Trispan	Cefixime	200 mg	Capsule	5's	112904	PKR 349.75	PKR 69.95/capsule	12% above median
Zyban	Bupropion	300 mg	Sustained-release tablet	2x10's	093381	PKR 941.33	PKR 47.07/tablet	47% below median
Zyban 150mg SR	Bupropion	150 mg	Sustained-release tablet	3x10's	093380	PKR 847.18	PKR 28.24/tablet	Near median
Zyban 150mg SR	Bupropion	150 mg	Sustained-release tablet	1x10's	093380	PKR 282.41	PKR 28.24/tablet	Near median
Zyban 150mg SR	Bupropion	150 mg	Sustained-release tablet	1x7's	093380	PKR 197.67	PKR 28.24/tablet	Near median
Zyban 150mg SR	Bupropion	150 mg	Sustained-release tablet	2x10's	093380	PKR 564.80	PKR 28.24/tablet	Near median

MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record

MedInfoBase. (2026). Seraph Pharmaceutical — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/seraph-pharmaceutical/

Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.

Seraph Pharmaceutical

What is sourced, and how recent is it?

Company profile

Company location

Portfolio at a glance

How complete is this profile?

Downloadable company intelligence charts

Therapeutic Portfolio Mix

Dosage Form Portfolio

Equivalent Price Position

Closest Portfolio Competitors

Therapeutic areas

Drug classes

Dosage forms

Deepest brand families

Unit-price positioning vs equivalent products

Portfolio overlap

Observed database signals

Medicine portfolio

Cite this record